此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

克罗恩病中度术后复发的管理:治疗升级的随机对照试验,POMEROL 试验。 (波美侯) (POMEROL)

Study type : A 30 months, multicentre, open-label strategic randomized controlled trial

Population : Chron's Disease (CD) patients with an i2 endoscopic postoperative recurrence in the year following ileocolonic resection (6-12months after ileocolonic resection).

Treatments :

Stratification at inclusion according to prophylactic therapy.

Patients randomized in 2 arms:

  • Status quo arm: if the patient received no prophylactic therapy, no treatment will be started; if the patient received a prophylactic therapy, the same will be continued at the same dose.
  • Therapy escalation arm: infliximab-CT-P13 will be started with two intravenous infusions of 5 mg per kg bodyweight at week 0 and week 2 and subcutaneous injections of 120 mg every 2 weeks from week 6 onwards.

Main objective : To evaluate the proportion of CD patients without endoscopic postoperative recurrence (i0-i1) at 12 months in the arm receiving therapy escalation compared to status quo arm in patients having an i2 endoscopic postoperative recurrence 6-12months after ileocolonic anastomosis with restoration of faecal stream.

研究概览

详细说明

Number of patients : 360 patients in approximatively 25 sites in France.

Recruitement period : The trial duration for each patients will be 12 months from radomization (18 to 24 months from screening (ie : post-operatively))

Endpoints:

Primary endpoints: Proportion of patients with an i0-i1 modified Rutgeerts score at 12 months.

Secondary endpoints:

  • Proportion of patients with an i3-i4 modified Rutgeerts score at 12 months

  • Proportion of patients with an i2b-i3-i4 modified Rutgeerts score at 12 months

  • Proportion of patients with an i0 modified Rutgeerts score at 12 months

  • PRO2 score at 12 months

  • Clinical postoperative recurrence within 12 months: average daily SF ≥ 3.5 and average daily AP score ≥ 1.5, AND

    • increased CRP compared to inclusion, at least + 10 mg/l
    • OR increased fecal calprotectin compared to inclusion, at least + 250 μg/g
  • Surgical recurrence within 12 months: need for a new ileocolonic resection

  • Endoscopic dilatation within 12 months: need for a balloon insufflation at the ileocolonic anastomosis during an ileocolonoscopy when a non-passable stenosis was present in patient having obstructive symptoms (CDOS > 4) before endoscopy

  • Time to clinical postoperative recurrence

  • Serious adverse events

  • Quality of life: EQ5D-5L questionnaire

  • Work productivity: Work Productivity and Activity Impairment questionnaire

研究类型

介入性

注册 (实际的)

213

阶段

  • 第四阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Paris、法国、75009
        • GETAID

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 75年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Crohn's disease diagnosed according usual criteria
  • Bowel resection with ileocolonic anastomosis performed removing all inflammatory lesions
  • Postoperative endoscopy performed between 6 and 12 months after ileocolonic anastomosis reaching the neoterminal ileum (patients who underwent a two stage surgical procedure are also eligible if the endoscopic evaluation is performed 6-12 months after restoration of the fecal stream)
  • Moderate endoscopic postoperative recurrence classified i2 according to the Rutgeerts score at 6-12 months, validated by a blinded central reading

Exclusion Criteria:

  • Patients with an ostomy
  • Ulcerative colitis or IBD type unclassified
  • Ileorectal or ileal pouch-anal anastomosis
  • Symptoms defined as average daily SF ≥ 3.5 and average daily AP score ≥ 1.5 having started after a free interval without symptoms of at least one month after surgery
  • Patients with obstructive symptoms of CD defined by a CDOS > 4
  • Patients exposed to infliximab before index surgery with a primary non-response (no clinical effect after 2 infusions at the discretion of the treating gastroenterologist) or history of infusion reactions to infliximab or history of detectable anti-infliximab antibodies
  • Patients treated with biological therapy (except for intraocular injections) or an investigational medical product after index surgery
  • Patients having started thiopurines or methotrexate more than 6 weeks after ileocolonic anastomosis with restoration of the fecal stream
  • Patients in whom not all inflammatory lesions have been removed at index surgery
  • Patients with active perianal Crohn's disease
  • Patients with a contraindication to infliximab: cancer in the 5 years prior to inclusion excluding non-melanoma skin cancer, active tuberculosis or untreated latent tuberculosis, moderate or severe heart failure, HIV or HBV infection (serology < 6 months), recent live vaccination (within 4 weeks of baseline)
  • Pregnant women
  • Patients under legal protection or unable to express their consent.
  • Patients not affiliated to a health insurance system.
  • Patients deprived of liberty by judiciary or administrative decision or hospitalized without consent or admitted in a sanitary or social institution for another reason than research.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
其他:Status quo arm

If the patient received no prophylactic therapy after resection, no treatments will be started.

If the patient received a prophylactic therapy after resection, the same will be continued at the same dose.

Stratification 1 : No treatments

Stratification 2 : Immunosuppressors at same dose

实验性的:Therapy escalation arm

Infliximab-CT-P13 will be started with two intravenous infusions of 5 mg per kg bodyweight at week 0 and week 2 and subcutaneous injections of 120 mg every 2 weeks from week 6 onwards.

Stratification 1: Infliximab-CT-P13

Stratification 2: Infliximab-CT-P13 in combination with immunosuppressors

其他名称:
  • 雷姆西马

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Number of patients with an i0-i1 modified Rutgeerts score at 12 months.
大体时间:Month12

Number of patients with an i0-i1 modified Rutgeerts score at 12 months.

Month12

次要结果测量

结果测量
措施说明
大体时间
Number of patients with an i3-i4 modified Rutgeerts score at 12 months
大体时间:Month 12

Number of patients with an i3-i4 modified Rutgeerts score at 12 months

Month 12
Proportion of patients with an i2b-i3-i4 modified Rutgeerts score at 12 months
大体时间:Month 12

Proportion of patients with an i2b-i3-i4 modified Rutgeerts score at 12 months

Month 12
Proportion of patients with an i0 modified Rutgeerts score at 12 months
大体时间:Month 12

Proportion of patients with an i0 modified Rutgeerts score at 12 months

Month 12
Patient Reporting Outcome score at 12 months.
大体时间:Screening, Baseline, week 2, week 6, Month 4, Month 8, Month 12

Patient Reporting Outcome score at 12 months will be assessed for the evaluation of disease activity (clinical remission).

Screening, Baseline, week 2, week 6, Month 4, Month 8, Month 12
Clinical postoperative recurrence
大体时间:Baseline, Month 4, Month 8, Month 12

Clinical postoperative recurrence within 12 months defined by : Average daily Stool Frequency ≥ 3.5 and average daily Abdominal Pain score ≥ 1.5, AND

  • increased CRP compared to inclusion, at least + 10 mg/l
  • OR increased fecal calprotectin compared to inclusion, at least + 250 μg/g

Average daily Stool frequency, average daily Abdominal Pain score, CRP and Calprotectin feacal will be combined to report the clinical postoperative recurrence (this outcome is is expressed without units)

Baseline, Month 4, Month 8, Month 12
Surgical recurrence within 12 months
大体时间:Baseline, Month 4, Month 8, Month 12

Surgical recurrence within 12 months defined by need for a new ileocolonic resection. Proportion of surgical recurrence within 12 months

Baseline, Month 4, Month 8, Month 12
Endoscopic dilatation within 12 months
大体时间:Baseline, Month 4, Month 8, Month 12

Endoscopic dilatation within 12 months defined by a need for a balloon insufflation at the ileocolonic anastomosis during an ileocolonoscopy when a non-passable stenosis was present in patient having obstructive symptoms (CDOS > 4) before endoscopy Proportion of endoscopic dilatation within 12 months

Baseline, Month 4, Month 8, Month 12
Time to clinical postoperative recurrence will be assessed
大体时间:Baseline, Month 4, Month 8, Month 12

Time to clinical postoperative recurrence will be assessed

Baseline, Month 4, Month 8, Month 12
Serious adverse events
大体时间:Screening, Baseline, Month 4, Month 8, Month 12

Occurence of Serious Adverse Events

Screening, Baseline, Month 4, Month 8, Month 12
Quality of life: EQ5D-5L questionnaires
大体时间:Baseline, week 2, week 6, Month 4, Month 8, Month 12

Quality of life will be assessed with the EQ5D-5L questionnaire

Baseline, week 2, week 6, Month 4, Month 8, Month 12
Work productivity and activity impairement questionnaires
大体时间:Baseline, week 2, week 6, Month 4, Month 8, Month 12

Work productivity and activity impairement will be assessed with work productivity and activity impairement questionnaires

Baseline, week 2, week 6, Month 4, Month 8, Month 12

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2021年12月21日

初级完成 (实际的)

2026年10月15日

研究完成 (实际的)

2026年10月15日

研究注册日期

首次提交

2021年8月18日

首先提交符合 QC 标准的

2021年9月28日

首次发布 (实际的)

2021年10月11日

研究记录更新

最后更新发布 (实际的)

2026年11月6日

上次提交的符合 QC 标准的更新

2026年11月4日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅